Carboxylmethylation affects the proteolysis of myelin basic protein by Staphylococcus aureus V8 proteinase.

Bovine myelin basic protein (MBP), charge isoform 1 (C1) was carboxylmethylated by the enzyme D-aspartyl/L-isoaspartyl protein methyltransferase (EC. 2.1.1.77) and the carboxylmethylated protein was subjected to proteolysis by sequencing grade staphylococcal V8 proteinase at pH 4.0 to identify its carboxylmethylated modified aspartate and/or asparagine residues which are recognized by this methyltransferase. Native MBP, C1 was treated similarly and the proteolysis products were compared, using electrophoretic, chromatographic and amino acid sequencing techniques. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) revealed differences in the kinetics of proteolysis between the native and the carboxylmethylated MBP, C1 which were confirmed using HPLC. Partial sequencing of the native and carboxylmethylated fragments eluting at about 29 min (P29) revealed cleavage of native MBP, C1 at Gly-127-Gly-128 and of the carboxylmethylated MBP, C1 at Phe-124-Gly-125. Additional evidence including tryptic subdigestion of carboxylmethylated P29 disclosed the following partial sequence for this peptide: Gly-Tyr-Gly-Gly-Arg-Ala-Ser-Asp-Tyr-Lys-Ser-Ala-His-Lys-Gly-Leu-Lys- Gly-His-Asp-Ala-Gln-Gly-Thr-Leu-Ser-Lys-Ileu-Phe-Lys-. This sequence matches MBP residues 125-154. As a result of these findings, Asp-132 and Asp-144 were identified as two of the modified (isomerized or racemized) methyl-accepting L-aspartates in MBP. The results of the proteolysis experiments wherein the sequencing grade staphylococcal V8 proteinase was used at the rarely tested pH of 4.0, rather than at its commonly tested pH of 7.8, also disclose that the proteinase totally failed to recognize and hence cleave the two Glu-X bonds (Glu-82-Asn-83 and Glu-118-Gly-119) of MBP, preferring to cleave the protein at a number of hitherto unreported sites.

Kinetics of carboxylmethylation of the charge isoforms of myelin basic protein by protein methyltransferase II.

The charge isoforms (C1-C5) of bovine myelin basic protein (MBP) were used as substrates for the rat brain enzyme protein carboxylmethyltransferase (PM II). The objective of these experiments was to ascertain whether the kinetic behavior of the MBP isoforms reflected differences in the structures of this molecular family. Initial velocity plots as a function of the MBP-isoform concentration showed significant differences (p less than 0.05) among the assayed isoforms except for isoforms C2 and C4. Under the conditions of our experiment all the curves exhibited a consistent sigmoidicity. The kinetic data were best fitted by a model, previously described for the enzyme D-beta-hydroxybutyrate dehydrogenase, in which two independent sites must be randomly occupied before any catalytic activity can occur. This mechanism is substantially different from that proposed by other investigators for similar PM II enzymes and other substrates. The differences in the rates of isoform carboxylmethylation are largely accounted for by the different apparent dissociation constants Ks and is explained on the basis of inherent structural differences among the charge isoforms.

Enzymatic inactivation of bradykinin by rat brain neuronal perikarya.

1. Bradykinin (Bk; Arg1-Pro2-Pro3-Gly4-Phe5-Ser6-Pro7-Phe8-Arg8) inactivation by bulk isolated neurons from rat brain is described. 2. Bk is rapidly inactivated by neuronal perikarya (4.2 +/- 0.6 fmol/min/cell body). 3. Sites of inactivating cleavages, determined by a kininase bioassay combined with a time-course Bk-product analysis, were the Phe5-Ser6, Pro7-Phe8, Gly4-Phe5, and Pro3-Gly4 peptide bonds. The cleavage of the Phe5-Ser6 bond inactivated Bk at least five fold faster than the other observed cleavages. 4. Inactivating peptidases were identified by the effect of inhibitors on Bk-product formation. The Phe5-Ser6 bond cleavage is attributed mainly to a calcium-activated thiol-endopeptidase, a predominantly soluble enzyme which did not behave as a metalloenzyme upon dialysis and was strongly inhibited by N-[1(R,S)-carboxy-2-phenylethyl]-Ala-Ala-Phe-p-aminobenzoate and endo-oligopeptidase A antiserum. Thus, neuronal perikarya thiol-endopeptidase seems to differ from endo-oligopeptidase A and endopeptidase 24.15. 5. Endopeptidase 24.11 cleaves Bk at the Gly4-Phe5 and, to a larger extent, at the Pro7-Phe8 bond. The latter bond is also cleaved by angiotensin-converting enzyme (ACE) and prolyl endopeptidase (PE). PE also hydrolyzes Bk at the Pro3-Gly4 bond. 6. Secondary processing of Bk inactivation products occurs by (1) a rapid cleavage of Ser6-Pro7-Phe8-Arg8 at the Pro7-Phe8 bond by endopeptidase 24.11, 3820ACE, and PE; (2) a bestatin-sensitive breakdown of Phe8-Arg9; and (3) conversion of Arg1-Pro7 to Arg1-Phe5, of Gly4-Arg9 to both Gly4-Pro7 and Ser6-Arg9, and of Phe5-Arg9 to Ser6-Arg9, Phe8-Arg9, and Ser6-Pro7, by unidentified peptidases. 7. A model for the enzymatic inactivation of bradykinin by rat brain neuronal perikarya is proposed.

The carboxylmethylation of cerebral membrane-bound proteins increases with age.

Recently, we have characterized a membrane-bound (mb) component of brain protein carboxylmethyltransferase II (PCMT) which effectively carboxylmethylates endogenous mb methyl-accepting proteins (MAPs). (Neurochem. Int., 10 (1987) 155). We have also shown that exposing mb-MAPs to mild alkali leads to a marked increase in their recognition by PCMT. Since one of the likely consequences of the alkaline treatment appears to be the deamidation of selected protein-bound asparagines or aspartates, followed by the formation, in their place, of D-or L-isoaspartates, it is reasonable to assume that mb-MAPs constitute unique targets for the mb-PCMT because they contain such unnatural aspartate residues. Testing the relevance of this notion to the aging of cerebral mb-MAPs we focus in this report on age-related changes involving mb-MAPs. When two-or six-times washed (in 50 mM NaPO4 buffer, pH 6.5) 17,500 g, 30-min membranes or Percoll-gradient purified synaptic membranes were prepared from young (3-4 months) and old (11-12 months) rat brains and were incubated with 20 microM [3H]methyl S-adenosyl-L-methionine at pH 6.0, mb-MAP carboxyl[3H]methylation was significantly more intense in the old than in the young membranes, no additional increase being noted at 28-35 months. Mb-MAP carboxylmethylation increases were confirmed over a wide range of membrane protein concentrations and incubation times and are taken to reflect age-related modifications of the primary structure of susceptible mb-MAPs. To investigate these, we incubated young and old membranes, as well as their Lubrol-Px (1%) extracts (30 min, 0 degree C), with 0.05 M NH4OH for 90 min at 37 degrees C, a treatment which left PCMT activity largely unaffected. Our findings reveal that the effect of the NH4OH treatment on the generation of carboxylmethylatable sites was markedly smaller in "old" than in "young" proteins, suggesting that "new" carboxylmethylatable sites are generated in susceptible mb-MAPs in situ, by a process accompanying, or otherwise marking, the natural aging of neural membrane proteins.

The characterization of a membrane-bound protein carboxylmethylation system in brain.

The membrane-bound component of the cerebral protein carboxylmethylation system, consisting of the membrane-bound enzyme protein carboxylmethyltransferase II (PCMT) and of selected membrane-bound methyl accepting proteins (MAP), is described. The cellular localization of this membrane-bound protein carboxylmethylation system is shown to include, in addition to nerve cell bodies and purified synaptosomes, astrocytes and oligodendroglia. The membrane-bound nature of the protein carboxylmethylation system was investigated and these studies revealed a tight association which exposure to several detergents could only partially solubilize. The membrane-bound PCMT could be shown to undergo activation after treatment with Na-deoxycholate and CHAPs, while after its detergent-induced solubilization PCMT activation was observed after Na-deoxycholate, Nonidet P-40 and Lubrol-P(X). Solubilization of the carboxylmethylation system in CHAPS appeared to be more effective at 0 degrees C than at 25 degrees C or 37 degrees C. Detergent treatment was shown to be deleterious to the MAPs as PCMT substrates, particularly when the exposure was extended to more than 1 h. These observations prompted exposure of the brain membranes and of their Lubrol-P(X) and Nonidet P-40 extracts to NH(4)OH, treatment which promotes the conversion of protein asparagine residues to atypical l-isoaspartate residues, recently shown (in synthetic peptides) to be the single most effective residue recognized for carboxylmethylation by PCMT. We found up to a 400% enhancement of the carboxylmethylation of solubilized membrane MAPs by the equally solubilized PCMT (which resisted the alkaline treatment virtually unscathed) after 90 min at 37 degrees C in 0.05 M NH(4)OH. However, when brain membrane Lubrol-P(x) extracts were first subjected to bis(I,I-trifluoroacetoxy)-iodobenzene, a reagent which converts the carboxyamide group of protein-bound asparagine to the corresponding primary amine, the amount of MAPs susceptible to be acted upon by 0.05 M NH(4)OH became greatly reduced. Finally, acidic slab gel electrophoresis of membrane-bound MAPs, carboxyl-[(3)H]-methylated by the membrane-bound PCMT, revealed the presence of about 12 radioactive protein bands, ranging in MW from under 20 KDa to about 90 KDa.

Cerebral methylations in epileptogenesis.

This chapter deals with the neurochemical consequences of the administration of the chemical convulsant agent L-methionine-dl-sulfoximine (MSO) on the brain of rodents. The principal notion is that this convulsant agent differs qualitatively from most quick-acting and predominantly lethal convulsant agents, commonly used in laboratory studies in epilepsy modeling because it has a preconvulsant latency period of several hours and also because it need not be fatal to the animals receiving it if they are properly managed during the preconvulsant period and following the first seizure attack. The historical profile of MSO as a useful and unique laboratory tool for neurochemical and molecular studies is briefly recounted, and the point is made that MSO is a close derivative of the amino acid L-methionine, which is used by each and every brain cell as a protein building block and as a precursor of the universal cellular methyl donor molecule, S-adenosyl-L-methionine. The importance of methylations, a set of reactions which consist in the transfer of the methyl group of S-adenosyl-L-methionine to several dozens of endogenous methyl acceptor molecules, small and large, is stressed and reviewed both historically and as this process relates to MSO epileptogenesis. The multiple effects of MSO on the methylation of small MW compounds, histamine being the working example, are reviewed. The involvement of phospholipid, nucleic acid, and protein methylations, all apparent targets of MSO action, in that they respond to the MSO challenge by a significant rate increase is elucidated. Finally, the effects of MSO at the functional level of brain receptor action are presented.(ABSTRACT TRUNCATED AT 250 WORDS)

Brain methylation and epileptogenesis: the case of methionine sulfoximine.

A brief review of the neurochemical effects of the convulsant agent L-methionine-dl-sulfoximine (MSO) on cerebral methylation reactions is presented. Our findings point to the involvement of a number of endogenous methyl acceptor molecules, including histamine, membrane phospholipids, and membrane proteins, in the mediation of the convulsant effect. Our findings also associate the inhibition of methylations by high levels of S-adenosyl-L-homocysteine in brain with protection against MSO-induced seizures. We propose that MSO acts by eliciting the acceleration of a regulatory methylation-demethylation sequence at key molecular sites, including the benzodiazepine receptor complex, which creates an imbalance in this sequence's normal mediation of convulsant-anticonvulsant mechanisms.

Developmental changes in protein carboxylmethylation and in the benzodiazepine receptor proteins in rat brain.

The intraventricular administration of [3H-methyl]-methionine resulted in a steady increase in carboxyl-[3H]methylated protein formation in the brain of developing rats (2-42 days). The analysis by gel filtration on Sepharose-4B of Lubrol-Px-solubilized membrane proteins, including benzodiazepine receptor proteins, revealed co-migration of carboxyl-[3H]methylated and [3H]flunitrazepam-binding protein species. The latter displayed a single peak at 2 days and 2-3 peaks subsequently. At 26 days the lighter of the two [3H]flunitrazepam and [3H]muscimol-binding peaks associated with the principal carboxyl-[3H]-methylated protein peak. The findings suggest the participation of carboxyl-methylation in the maturation of benzodiazepine receptor proteins.

Biosynthesis of polyamines in mouse brain: effects of methionine sulfoximine and adenosylhomocysteine.

This study examines the consequences on cerebral polyamine biosynthesis of increases and decreases in cerebral methylation. Increases were elicited by administering the convulsant agent methionine sulfoximine (MSO) and decreases by elevating in vivo the cerebral levels of the methylation inhibitor S-adenosylhomocysteine. Following the intraventricular (i.vt.) administration of one of the two possible polyamine precursors, [1,4-14C]putrescine, the specific radioactivity (sra) of the newly formed [14C]spermidine remained unchanged. Conversely, after i.vt. L-[3,4-14C]methionine, the other polyamine precursor, significantly higher sra values for [14C]spermidine and [14C]spermine were recorded in the brains of the MSO-treated animals. [14C]S-adenosylmethionine in the brain of the MSO-treated animals was also more highly labeled following [1-14C]-methionine, indicating its accelerated formation relative to controls. We also investigated the effect of the administration of adenosine + homocysteine, a treatment that results in elevated brain adenosylhomocysteine levels, on polyamine biosynthesis from [3,4-14C]-methionine. The results of these experiments show both significantly lower sra values for [14C]spermidine and [14C]spermine and significantly higher than control endogenous methionine levels, a clear sign of the existence of a retardation in the conversion of methionine to polyamines under these conditions. In conclusion, the present study demonstrates that while interference with cerebral methylation results in significant alterations of the rate of formation of the methionine moiety of spermidine and spermine, it has no effect on the entry of the putrescine moiety into the two polyamine molecules.

Possible role of increased brain methylation in methionine sulfoximine epileptogenesis: effects of administration of adenosine and homocysteine thiolactone.

An intraventricular pulse of [14COOH]L-methionine to mice pretreated with the convulsant L-methionine-dl-sulfoximine (MSO) resulted in significantly higher than control specific radioactivity values of cerebral [14COOH]L-methionine (Met), [14COOH]S-adenosyl-L-methionine (AdoMet) and [14COOH]S-adenosyl-L-homocysteine (AdoHcy). MSO administration (3 hr) also decreased brain steady-state levels of Met, AdoMet, and AdoHcy. Following an intraventricular pulse of [3H-methyl]L-methionine, the levels of [3H-methyl]phosphatidylmonomethylethanolamine and of membrane associated and soluble [3H-methyl]carboxylmethylated proteins were increased over corresponding saline-treated controls. The activity of cerebral histamine N-methyltransferase was also increased after MSO treatment. The administration of a combination of adenosine and homocysteine thiolactone to MSO-pretreated animals counteracted the MSO-induced decreases in brain Met, AdoMet, and AdoHcy as well as the increase in histamine N-methyltransferase activity. In addition, administration of adenosine together with homocysteine thiolactone decreased the incidence of, and increased the latency to MSO seizures, with the most effective anticonvulsant action occurring when cerebral AdoHcy levels were at their highest.

Alpha-aminoisobutyric acid uptake in primary cultures of astrocytes.

Homotypically pure cultures of rat brain astrocytes were used to examine some aspects of non-neuronal A-system (alanine preferring) amino acid uptake. The A-system specific probe, alpha-aminoisobutyric acid is transported rapidly, and a steady state distribution ratio of 9-25 is reached after 30 minute incubations. Kinetic estimates derived from uptake progress curves indicated a Km of 1.35 mM and a Vmax of 133 nmol/min/mg protein. Uptake is reduced in the absence of either Na+ or K+. Elevations in extracellular K+, a putative metabolic modulator of neuroglia, did not affect uptake.

Methionine sulfoximine in vivo modifies the tRNALys pool of developing rat brain.

tRNA was extracted from brains of 3-, 8-, and 18-day-old rats that were injected intracerebrally, 45 min before death, with [3H]methyl methionine or [8-3H]guanosine, and intraperitoneally, 3 h before death, with L-methionine-dl-sulfoximine (MSO), a methylation-activating convulsant agent. Although there was no effect of age or of MSO on the per gram yield of tRNA, its specific radioactivity (dpm/A260) was highest at 3 days in both the control and the MSO groups. Age- and MSO-related changes in tRNALys content of the brain tRNA pool were investigated by means of benzoylated DEAE-cellulose (BDC) and reverse-phase chromatography (RPC). BDC chromatography revealed tRNALys species in the brains of the MSO-treated animals that were absent in control brains. Of particular interest was the finding that differences in RPC-5 chromatographic mobility between control and MSO-tRNALys species were abolished by conversion of lysyl-tRNA, suggesting that the MSO-elicited change(s) in tRNALys structure involved the binding site(s) for lysine. Two additional findings were made: (a) lysine acceptance by the [3H]methyl-labeled tRNALys purified from brains of the MSO-treated animals was higher than that of controls at 18 days; and (b) omission of the BDC chromatographic step accentuated the differences in mobility on RPC-5 columns between tRNALys species of control and MSO-treated animals. Lastly, we found that some tRNALys species of control and MSO-treated brains contained significantly different proportions of N2-methyl guanine and 1-methyl adenine, relative to controls. These MSO-elicited changes in the methyl base content of tRNALys of immature rat brain are the first evidence of an alteration of brain tRNA structure by a centrally acting excitatory agent.

Beta-alanine uptake is not a marker for brain astroglia in culture.

The properties of the beta amino acid transport system were examined in cultivated rat brain astrocytes, using the specific probe, beta-alanine. The uptake of beta-alanine is thought to be glial specific. Beta-alanine was not actively transported and the intracellular accumulation was not altered by coincubation with GABA, alanine, glutamate, or methionine. We suggested therefore that beta-alanine is passively taken up by a mechanism distinct from the transport system for GABA.

Potassium modulation of methionine uptake in astrocytes in vitro.

Methionine participates in a large variety of metabolic pathways in brain, and its transport may play an important regulatory role. The properties of methionine uptake were examined in a preparation of neonatal rat brain astrocytes. Uptake is linear for 15 minutes, up to 2.5 microM. At steady state conditions, methionine is concentrated 30-50-fold. Measured methionine homoexchange accounts for a significant fraction of uptake at concentrations greater than 10 microM. We recently reported that methionine uptake is decreased by elevations in extracellular K+. Potassium induced efflux cannot account for this apparent effect; and thus for concentrations less than 2.5 microM, and for short times of incubation, measured rates of methionine uptake represent unidirectional flux. At extracellular concentrations of K+ equal to 6.9 mM, the apparent Vmax of methionine transport is 182 pmol/min/mg protein, and the Km is 1.3 microM. Where K+ is shifted to 11.9 mM, the Km remains unchanged, and the Vmax is reduced by half.

Decreased transmethylation of biogenic amines after in vivo elevation of brain S-adenosyl-l-homocysteine.

The ability of S-adenosyl-L-homocysteine (AdoHcy) to inhibit biologic transmethylation reactions in vitro has led us to explore the possibility of pharmacologically manipulating AdoHcy levels in vivo and examining the consequences of these alterations on the transmethylation of some biogenic amines. Swiss-Webster mice were injected intraperitoneally with different doses of adenosine (Ado) and D, L-homocysteine thiolactone (Hcy) and were killed at various times thereafter. S-Adenosyl-methionine (AdoMet) and AdoHcy concentrations were determined by using a modified isotope dilution-ion exchange chromatography-high pressure liquid chromatography technique sensitive to less than 10 pmol. Increasing doses of Ado + Hcy (50-1000 mg/kg of each) produced a dose-related increase in blood, liver, and brain AdoHcy levels. At a dose level of 200 mg/kg Ado + Hcy, AdoHcy levels were markedly elevated, with minimal concomitant perturbations of AdoMet. This elevation was maximal 40 min after giving Ado + Hcy, returning to control values within 6 h. Ado + Hcy treatment resulted in decreased activities of catechol-O-methyltransferase, histamine-N-methyltransferase, and AdoHcy hydrolase in vitro. The cerebral catabolism of intraventricularly administered [(3)H]histamine (HA) was decreased in a dose-related manner by Ado + Hcy treatment as evidenced by higher amounts of nonutilized [(3)H]HA in brain, concurrent decreases in [(3)H]methylhistamine formation, and decreases in the transmethylation conversion index. Steady state levels of HA also showed dose-related increases after Ado + Hcy treatment. It is concluded that injections of Ado + Hcy can markedly elevate AdoHcy levels in vivo, which can, in turn, decrease the rate of transmethylation reactions.